Results of a phase I/II clinical trial of CALEC, limbal epithelial cell grafts generated by an innovative and rigorously standardized manufacturing protocol, showing safety and feasibility for treating LSCD.
- Ula V. Jurkunas
- Aaron R. Kaufman
- Jerome Ritz
